單純皰疹病毒治療藥市場:各藥物類型，各給藥途徑，各地區-規模，佔有率，展望，機會分析，2023年～2030年

Herpes Simplex Virus Treatment Market, By Drug Type, By Route of Administration, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: 2023年04月12日 | 出版商:

Coherent Market Insights | 英文 171 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

單純皰疹病毒 (HSV) 是一種引起生殖器和口腔皰疹的病毒感染。它是一種傳染性很強的病毒，會引起感染。HSV有兩種類型，例如HSV-1和HSV-2。生殖器皰疹無法治癒，但是，每天使用抗病毒藥物可以預防或縮短爆發時間，並減少將其傳播給他人的機會。因此，全球對安全有效的單純皰疹病毒治療的需求不斷增加。

單純皰疹病毒感染流行率增加、臨床試驗數量增加、對安全有效 HSV 治療的需求增加以及人們對單純皰疹病毒認識的提高預計是在預測期內促進全球皰疹單純病毒治療市場成長的主要因素。

本報告對全球單純皰疹病毒治療市場進行了深入分析，並提供了預測期(2023-2030年)的市場規模(百萬美元)和年複合成長率(CAGR %)，以 2022年為基準年。

The herpes simplex virus (HSV) is a viral infection that causes genital and oral herpes. It is a very contagious virus that causes infections. There are two types of HSV, such as HSV-1 and HSV-2. There is no cure for genital herpes, however, daily use of antiviral medicines can prevent or shorten outbreaks, and reduce the chance of spreading it to others. Thus, there is an increasing demand for safe and effective herpes simplex virus treatment worldwide.

Market Dynamics:

Increase in prevalence of infections of the herpes simplex virus, rise in number of clinical trials, increase in demand for safe and effective HSV treatment, and increase in awareness among people about herpes simplex virus are major factors expected to augment the growth of the global herpes simplex virus treatment market over the forecast period.

For instance, in October 2021, United BioPharma, Shanghai Public Health Clinical Centre, and Department of Microbiology (Cheng Kung University) and Immunology teamed up to investigate the efficacy of UB-621, a best-in-class long-acting medicine for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and 2). Moreover, the World Health Organization (WHO) and partners support research to develop new strategies for prevention and control of HSV infections.

Key features of the study:

This report provides in-depth analysis of the global herpes simplex virus treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global herpes simplex virus treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Fresenius SE & Co. KgaA, Glenmark Pharmaceuticals, Carlsbad Tech, GlaxoSmithKline PLC, Zydus Cadila, Epi Health LLC, Viatris Inc., Apotex Inc., Teva Pharmaceuticals Industries Ltd., and Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.), among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global herpes simplex virus treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global herpes simplex virus treatment market.

Detailed Segmentation:

Global Herpes Simplex Virus Treatment Market By Drug Type:
- Acyclovir
- Valacyclovir
- Famciclovir
- Other Drugs
Global Herpes Simplex Virus Treatment Market By Route of Administration:
- Oral
- Injection
- Topical
Global Herpes Simplex Virus Treatment Market By Geography:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Company Profiles:
- Fresenius SE & Co. KgaA
- Glenmark Pharmaceuticals
- Carlsbad Tech
- GlaxoSmithKline PLC
- Zydus Cadila
- Epi Health LLC
- Viatris Inc.
- Apotex Inc.
- Teva Pharmaceuticals Industries Ltd.
- Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.)

Market Dynamics
- Rise in prevalence of infections of the herpes simplex virus
- Social stigma about sexually transmitted diseases (STDs)
- Increase in demand for safe and effective HSV therapeutics
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Herpes Simplex Virus Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Herpes Simplex Virus Treatment Market, By Drug Type, 2017-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Acyclovir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Valacyclovir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Famciclovir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Other Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Herpes Simplex Virus Treatment Market, By Route of Administration, 2017-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

7. Global Herpes Simplex Virus Treatment Market, By Geography, 2017-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)

8. Competitive Landscape

Fresenius SE & Co. KgaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Carlsbad Tech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Zydus Cadila
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Epi Health LLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Apotex Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceuticals Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views